麗珠醫藥(01513.HK):天津同仁堂創業板IPO申請獲深交所受理
格隆匯6月30日丨麗珠醫藥(01513.HK)公佈,天津同仁堂於近日向深交所提交了首次公開發行股票並在創業板上市的申請,並於2021年6月28日取得深交所出具的《關於受理天津同仁堂集團股份有限公司首次公開發行股票並在創業板上市申請文件的通知》(深證上審〔2021〕265號),深交所對天津同仁堂首次公開發行股票並在創業板上市的申請文件予以受理。天津同仁堂將按照中國證券監督管理委員會及深交所的相關要求,配合做好發行上市的審核工作。
目前,深交所受理了天津同仁堂首次公開發行股票並在創業板上市的申請,還需對此次申請進行審核,能否獲得深交所的核準尚存在不確定性。若公司所持天津同仁堂的股份上市,因目前上述股份的發行價格未確定,具體的收益尚無法估計,對公司未來財務狀況及經營成果的影響亦無法確定。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.